dccadefed

Peter Neil

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Peter Neil

  • uploads///Part  Graph
    Basic Materials

    What Do Analysts Expect for Celanese’s 2Q16 Net Profit Margins?

    Analysts expect Celanese’s (CE) net profit margin to be ~16% for 2Q16. This compares to 16.6% in 2Q15 and 18.7% in 1Q16.

    By Peter Neil
  • uploads///Part  recommendations
    Basic Materials

    Wall Street’s Views and Recommendations for PPG Industries

    The number of analysts covering PPG Industries (PPG) has risen from 21 to 22. About 55.0% of them have recommended a “buy” for the stock.

    By Peter Neil
  • uploads///part
    Company & Industry Overviews

    Why Is Deere Trading at a Discount to Caterpillar?

    As of December 30, 2016, Deere (DE) was trading at a one-year forward PE multiple of 22.6x compared to Caterpillar’s (CAT) of 30.6x.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie, Lead Performer of the Pharmaceutical Subgroup

    AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.

    By Peter Neil
  • uploads///Part  Olin
    Basic Materials

    Olin Surged Ahead in August: Here’s Why

    Olin Corporation (OLN) turned out to be one of the best performers among the specialty segments in August.

    By Peter Neil
  • uploads///Part  Graph
    Basic Materials

    Why Did Dow’s Consumer Solutions Segment’s Revenue Rise in 2Q16?

    The Consumer Solutions segment is Dow Chemical’s lowest revenue generator. In 2Q16, the segment reported revenue of $1.3 billion.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Announces Data from Phase 2 Study of PK Deficiency

    Agios Pharmaceuticals was one of the top performers among the small-cap segment within the iShares Nasdaq Biotechnology ETF (IBB) on June 13, 2016.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Akorn’s Revenue

    In 2014, prescription pharmaceuticals generated revenue of $542.84 million, and consumer health generated revenue of $50.23 million— 91.5% and 8.5% of total revenue, respectively.

    By Peter Neil
  • uploads///Part  CE
    Basic Materials

    Celanese Increases Product Prices, Stock Gains Momentum

    On May 18, Celanese (CE) announced price hikes for several of its products. The price increase will be effective from June 1.

    By Peter Neil
  • uploads///Part  Q  HBT HON
    Earnings Report

    How Honeywell’s Home & Building Technologies Did in Q2 2018

    Honeywell International’s (HON) HBT (Home & Building Technologies) segment is its third-largest revenue contributor.

    By Peter Neil
  • uploads///Part  Dividend Yield
    Company & Industry Overviews

    3M’s Dividend Yield on a (Slow) Sliding Path

    As of December 6, 2017, 3M’s (MMM) dividend yield is ~2%, the lowest in the past four years.

    By Peter Neil
  • uploads///Part  GRA
    Basic Materials

    W.R. Grace Signs a Spree of New Contracts

    On November 27 and 28, 2017, W.R. Grace (GRA) signed a spree of new contracts for its Unipol license.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XBI Recovers from Its Slump

    The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Biogen Stock Fell for the Week Ending July 24

    For the week ending July 24, 2015, Biogen (BIIB) stock fell by -25.86%. The stock fell based on the downward revision of its 2015 revenue.

    By Peter Neil
  • uploads///LYB Part  Q Earnings
    Earnings Report

    Why Did LyondellBasell’s 3Q16 Earnings Miss Estimates?

    LyondellBasell (LYB) reported adjusted EPS (earnings per share) of $2.31 in 3Q16 compared to $2.80 in 3Q15, implying a fall of 17.5%.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Benchmark Indexes Continue to Outperform IBB and XBI

    The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.

    By Peter Neil
  • uploads///Part  Valuations Q Pre earnings
    Basic Materials

    How RPM International’s Valuation Compares

    Forward price-to-earnings ratio Previously, we discussed analysts’ views on RPM International (RPM). In this part, we’ll compare RPM’s forward PE (price-to-earnings) ratio with peers’. As of December 20, 2017, RPM’s one-year forward PE ratio stood at 17.5x, while peer PPG Industries (PPG) had a PE ratio of 17.6x. Forward PE ratios consider a company’s estimated EPS (earnings […]

    By Peter Neil
  • uploads///Part
    Miscellaneous

    A Quick Look at a Few Chemical Companies in 2016

    In this series, we’ll take a look at the performances of a few top chemical companies and how the policies of Trump and Clinton could impact those companies.

    By Peter Neil
  • uploads///Part  HBT
    Earnings Report

    How HON’s Home and Building Technologies Revenue Trended in 1Q17

    Honeywell’s (HON) Home and Building Technologies (or HBT) segment is a new segment that began reporting in 3Q16.

    By Peter Neil
  • uploads///Title
    Earnings Report

    Honeywell Stock since First-Quarter Earnings

    Honeywell (HON) is set to announce its Q2 2018 earnings on July 20 before the market opens. Since Q1, the stock has risen 2.4%.

    By Peter Neil
  • uploads///Part  Electronics Q
    Earnings Report

    What Drove 3M’s Electronics and Energy Segment’s Revenue in 3Q17

    3M’s (MMM) Electronics and Energy segment contributed a revenue share of 17.30% in 3Q17, compared to a revenue share of 16.80% in 3Q16—an increase of 0.50 percentage points on a year-over-year basis.

    By Peter Neil
  • uploads///Q  construction and Forestry
    Earnings Report

    DE’s Construction and Forestry Segment Reports Expanded Q2 Margin

    In the second quarter of fiscal 2019, Deere’s (DE) Construction and Forestry segment reported revenue of $2.99 billion.

    By Peter Neil
  • uploads///Part  price
    Company & Industry Overviews

    Can Deere Stock Continue Its Recovery?

    So far in 2018, Deere (DE) has underperformed the broader market S&P 500 (SPY).

    By Peter Neil
  • uploads///Part  Dividend
    Company & Industry Overviews

    Albemarle’s Dividend to Shareholders of Record on June 15

    On May 11, 2017, Albemarle (ALB) announced that its quarterly dividend is $0.32 per outstanding share.

    By Peter Neil
  • uploads///Part  Recommendations
    Basic Materials

    Wall Street Analysts’ Views on Praxair ahead of 4Q17 Earnings

    Of the 20 analysts currently tracking Praxair, 65% of them have recommended a “buy,” and 30% have recommended a “hold.”

    By Peter Neil
  • uploads///Part  Short Interest November
    Company & Industry Overviews

    ITW’s Short Interest Is at Its Highest Point: What Could It Mean?

    In the latest short interest report, the data indicated that Illinois Tool Works’ short interest was at its highest point of 2018.

    By Peter Neil
  • uploads///Part  Q earnings
    Earnings Report

    Axalta’s 4Q16 Adjusted EPS Manages to Meet Expectations

    Axalta Coating Systems (AXTA) reported adjusted EPS (earnings per share) of $0.29 for 4Q16 and managed to meet analysts’ expectation of $0.29.

    By Peter Neil
  • uploads///Part  HONQ
    Earnings Report

    Why Are Analysts Expecting Honeywell’s EPS to Rise in 4Q16?

    As of January 20, 2017, Wall Street analysts expect Honeywell (HON) to post adjusted EPS (earnings per share) of $1.74 in 4Q16.

    By Peter Neil
  • uploads///Part  IFF Q DVD
    Basic Materials

    A Look at IFF’s Second-Quarter Dividend

    On July 6, International Flavors & Fragrances (IFF) is set to pay its Q2 2018 cash dividend to common equity shareholders as of June 25.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Falls as Energy Sector Negatively Influences the Market

    The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.

    By Peter Neil
  • uploads///PArt  Recommendations
    Company & Industry Overviews

    How Much Upside Do Analysts See for Honeywell?

    For Honeywell, 79% of the analysts recommended a “buy,” 21% recommended a “hold,” and none of the analysts recommended a “sell” as of September 6.

    By Peter Neil
  • uploads///Part
    Basic Materials

    Dow Chemical and Sadara Announce Start-Up of Mixed Feed Cracker

    On August 29, 2016, Sadara Chemical (SADARA), a joint venture of Dow Chemical (DOW), and Saudi Aramco announced the start-up of its mixed feed cracker.

    By Peter Neil
  • uploads///Part  Revenue
    Basic Materials

    Why Analysts Are Expecting PPG Industries’ Revenues to Fall in 3Q17

    As of October 10, analysts expect PPG Industries (PPG) to post revenues of $3.75 billion in 3Q17, which would be a decline of 1.1% over the previous year.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Grifols and Myriad Traded above the 100-Day Moving Averages

    Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Analyzing DuPont’s Stock Performance in 2017

    With DuPont stock continuing to rise, it’s trading 8.1% above its 100-day moving average of $72.10. The movement indicates the stock’s upward trend.

    By Peter Neil
  • uploads///SWK Part Prices
    Company & Industry Overviews

    Stanley Black & Decker Had a Stellar Performance

    So far, Stanley Black & Decker (SWK) has given investors good returns among its industrial peers. As of June 5, Stanley Black & Decker has risen 20.70%.

    By Peter Neil
  • uploads///Part  Earnings
    Earnings Report

    Can 3M Beat Analysts’ Earnings Estimates in 4Q17?

    3M (MMM) is expected to post earnings per share (or EPS) of $2.01 in 4Q17, an increase of 6.9% over 4Q16.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Rises in Contrast to a Flat Market

    XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.

    By Peter Neil
  • uploads///Part  Revenues Q
    Basic Materials

    RPM International Reports Strong Revenue Growth in Fiscal 1Q18

    RPM International (RPM) reported record first-quarter revenue in fiscal 1Q18.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte and Neurocrine Trade above 100-Day Moving Averages

    On September 4, 2015, Incyte (INCY) closed trading at $115.88 and continued to trade above 20-day, 50-day, and 100-day moving averages. The stock outperformed the IBB.

    By Peter Neil
  • uploads///Part  Q Fragrances
    Basic Materials

    Why IFF’s Fragrances Segment’s Profit Fell in 3Q17

    The Fragrances segment of International Flavors and Fragrances (IFF) contributes the most to IFF’s overall revenue.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    How Are IBB’s American Depositary Receipts Performing?

    The ADRs of the iShares Nasdaq Biotechnology ETF (IBB) had negative returns of 1% for the week ended December 4, 2015. IBB provides good exposure to international biotech stocks.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Analyzing XLV’s Trend on Different Moving Averages

    On June 14, XLV closed at $71.32. It was trading above its 20-day, 50-day, and 100-day moving averages. XLV’s 20-day moving average was $71.05.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Analyzing IBB’s Moving Averages

    As of June 13, 33% of IBB’s stocks were trading above their 20-day moving averages and 43% were trading above their 50-day moving averages.

    By Peter Neil
  • uploads///PPG Part  Q
    Earnings Report

    Why Analysts Think PPG Industries’ 3Q Net Profit Margin Fell

    As of October 11, 2016, Wall Street analysts are expecting PPG Industries (PPG) to post a net profit margin of 10.9%.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Ultragenyx Woos Investors with Good Returns in Mid-Cap Space

    Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.

    By Peter Neil
  • uploads///Part  Graph
    Basic Materials

    How Are Analysts Rating Dow Chemical ahead of 2Q16 Earnings?

    As of July 15, 2016, Dow Chemical’s (DOW) consensus 12-month target price is $58.70. That indicates a return potential of 12.8% from its closing price of $52.06 on July 15.

    By Peter Neil
  • uploads///Part  Prices DEC
    Basic Materials

    Reviewing Albemarle’s Stock Performance in 2017

    In 2017, Albemarle (ALB) stock made solid gains, rising 49.2% year-to-date. ALB outperformed the SPDR S&P 500 ETF (SPY), which returned 19.6% for the year.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    IBB’s American Depository Receipts Outperformed on October 15

    The iShares Nasdaq Biotechnology ETF (IBB) gives investors exposure to the international market by investing in ADRs (American depository receipts).

    By Peter Neil
  • uploads///HON Short interest Q Pre
    Earnings Report

    Honeywell’s Short Interest Continues to Stay under 1%

    The latest report on September 28 suggests that Honeywell’s short interest remained under 1% of the outstanding shares.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status

    In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.

    By Peter Neil
  • uploads///Part  DVD
    Company & Industry Overviews

    The Facts on 3M’s 3Q17 Dividend

    On September 12, 3M will pay a dividend of ~$1.18 per share. Investors holding the stock on or before the record date of August 25, 2017, are eligible.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XLV Was Trading Higher after Paying Dividends

    The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///LYB Recommendations Q pre
    Basic Materials

    How Wall Street Analysts Rate LyondellBasell ahead of 1Q18 Earnings

    The analyst consensus target price for LyondellBasell is $116.82, implying a return potential of 8.5% over the closing price of $107.68 as of April 20, 2018.

    By Peter Neil
  • uploads///Part  Recommendations
    Company & Industry Overviews

    What’s the Latest Street View of APD?

    As of June 19, of the 20 analysts actively tracking APD stock, 60% had recommended a “buy,” while 30% of the analysts had recommended a “hold.”

    By Peter Neil
  • uploads///stock trading monitor desk
    Company & Industry Overviews

    Innovative Industrial Properties Declared Q1 Dividend

    On March 12, Innovative Industrial Properties’ board declared its first-quarter dividend. The company declared a dividend of $0.45 per share.

    By Peter Neil
  • uploads///Part  Graph
    Basic Materials

    Will PPG Industries’ Glass Segment Cease to Exist in 3Q16?

    In 2Q16, PPG Industries’ Glass segment contributed ~7% of total revenue, reporting revenue of $282 million in 2Q16, as compared to $279 million in 2Q15.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Horizon Rose and Outperformed IBB’s Mid-Cap Stocks

    Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.

    By Peter Neil
  • uploads///Part  Caterpillars interest coverage
    Company & Industry Overviews

    Caterpillar: Is Debt Servicing a Big Issue?

    Caterpillar has been generating strong free cash flows. In the past five years, Caterpillar has generated an average free cash flow of ~$4.0 billion per year.

    By Peter Neil
  • uploads///Part  analysts ratings
    Company & Industry Overviews

    3M: Why Are Analysts Cautious?

    Analysts’ consensus on 3M indicates a target price of $211.50, which implies a marginal gain of 0.5% over the closing price as of October 9.

    By Peter Neil
  • uploads///Part  IFF
    Company & Industry Overviews

    International Flavors & Fragrances to Raise $500 Million

    On May 15, 2017, International Flavors & Fragrances (IFF) announced its intention to raise $500.0 million in senior notes due in 2047.

    By Peter Neil
  • uploads///Part  graph
    Basic Materials

    Why LYB’s Olefins and Polyolefins – EAI Revenue Fell in 2Q16

    In 2Q16, LyondellBasell’s (LYB) Olefins & Polyolefins – Europe, Asia, and International (or EAI) segment reported revenue of $2.7 billion.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study

    The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Valuations
    Basic Materials

    Westlake Chemical’s Valuation: Still Better Than Peers

    As of December 4, 2017, Westlake Chemical’s (WLK) one-year forward PE (price-to-earnings) multiple is 15.10x.

    By Peter Neil
  • uploads///Part
    Macroeconomic Analysis

    What Are Analysts’ Recommendations for DuPont?

    Analysts’ consensus indicates a 12-month target price for DuPont at $78.10—a return potential of 5.5% from its closing price of $74.03 on January 11.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Did IFF’s 3Q16 Results Hurt Its Stock Price?

    International Flavors and Fragrances’ (IFF) performance from November 1, 2016, to December 23, 2016, wasn’t pleasant. Let’s take a look at its dividend, valuations, and more.

    By Peter Neil
  • uploads///Part  PX
    Basic Materials

    Praxair to Supply Gases for EverDisplay Optronics in China

    On January 22, 2018, Praxair (PX) announced that it has entered a long-term contract with Everdisplay Optronics (EDO), a China-based producer of 4.5 generation AMOLED displays.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Express Scripts Trades Above Its 100-Day Moving Average

    Express Scripts Holdings rose 0.4%. The company was in the news on November 10 when it announced that it would remove Linden Care Pharmacy from its network.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8

    The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Moving Averages Are on the Rise

    For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks

    Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Seattle Genetics Leads XBI Mid-Cap Stocks

    Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Incyte Guidance on Jakafi Sends Stock High

    On May 23, 2016, Incyte (INCY) was the biggest gainer among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) with a gain of 3.9%.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study

    The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB ADRs Outperform Benchmark for August 10–17, 2015

    The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.

    By Peter Neil
  • uploads///Part  HONQ
    Earnings Report

    Analysts Expect More than $10 Billion in Revenue for Honeywell

    Honeywell (HON) is announcing its 4Q16 earnings on January 27, 2017.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    PPG Industries’ Stock Price Is Still Under Pressure Post-3Q16

    PPG Industries’ (PPG) stock performance from November 1, 2016, to December 29, 2016, has been very mild, with a return of 1.6%.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data

    On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///Part  LYB
    Company & Industry Overviews

    LyondellBasell Announces New Share Repurchase Program

    On May 24, 2017, LyondellBasell’s (LYB) board authorized a new share repurchase program. It can repurchase up to 10% of its outstanding shares over the next 18 months.

    By Peter Neil
  • uploads///Part  PPG
    Basic Materials

    PPG Industries Will Acquire The Crown Group

    On July 20, 2017, PPG Industries (PPG) announced that it has entered into a definitive agreement to acquire The Crown Group.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    How Does XBI Compare to Its 100-Day Moving Average?

    The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Part  Q pre earnings
    Earnings Report

    Why Are Analysts Expecting Axalta’s Revenue to Rise in 4Q16?

    Analysts are expecting Axalta (AXTA) to post revenue of $1.02 billion in 4Q16. That’s a 1.2% rise year-over-year compared to $1.01 billion in 4Q15.

    By Peter Neil
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    IMMU and ACRX Outperform in the Biotech Downdraft

    Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. The stock closed at $2.08.

    By Peter Neil
  • uploads///Part  PMT
    Earnings Report

    Honeywell’s Performance Materials and Technologies: Why It Fell

    Honeywell’s (HON) Performance Materials and Technologies (or PMT) segment accounted for 22.2% of HON’s total revenue in 2Q17.

    By Peter Neil
  • uploads///Part  revenues
    Earnings Report

    Organic Growth Drives Up 3M’s 1Q17 Revenues

    The rise in 3M’s revenue was primarily driven by better-than-expected organic growth across all segments, with the exception of the Consumer segment.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///PArt  Revenues
    Earnings Report

    Why Analysts Expect Honeywell’s Revenues to Fall in 2Q17

    Honeywell signed an agreement with VietJet Air to supply 98 auxiliary power units to its fleet of 135 Airbus A320s. The deal was valued at $100 million, which includes maintenance services for 12 years.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How Celgene Reacted to Positive Clinical Trials on October 26, 2015

    Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Radius Continued to Fall despite Positive Data on Osteoporosis

    Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Part  ALB
    Company & Industry Overviews

    Albemarle Aims to Double Lithium Production in Australia

    On March 16, 2017, Albemarle (ALB) announced that it will double its lithium production capacity at its spodumene mine in Greenbushes, Australia.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Quest Gains after Acquisition of Clinical Laboratory Partners

    Quest Diagnostics (DGX) gained 2.9% on March 1, 2016, as it announced the completion of Outreach Laboratory

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Adeptus Health Leads the Small-Cap Space with 3.6% Gain

    Adeptus Health (ADPT) rose by 3.6% on November 10, 2015. The stock rose following its announcement that it had officially opened its first Texas hospital.

    By Peter Neil
  • uploads///Part  Graph
    Earnings Report

    Horizon Pharma Appears to Be on an Acquisition Spree

    Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.

    By Peter Neil
  • uploads///Title
    Basic Materials

    Praxair Secures a New Long-Term Contract

    Praxair has entered into a long-term agreement to supply oxygen for Fulcrum BioEnergy’s Sierra BioFuels Plant in Storey County, Nevada.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.